To further characterize the effects of Dox on CD133 expression, three different cancer cell lines, NCCIT, human embryonic carcinoma NTERA2, and colon adenocarcinoma LoVo, were treated with varying doses of Dox. The gene discussed is PROM1; the disease is embryonal carcinoma.